PZQ enantiomers were then administered concomitantly with pro-fibrogenic TGF-β1 in the in vitro InSight Human Liver Fibrosis Model 3D system, a model where fibrosis onset parallels the addition of the drug for assessment of preventive potential, similarly to the CCl4-based model. This evidence concerns the gene TGFB1 and Hepatic fibrosis.